Sorry, ‘Dr. Google.’ ChatGPT and Claude are now getting into the business of providing health advice.

Large Language Models (LLMs) such as ChatGPT and Anthropic's Claude are increasingly encroaching on the territory of traditional health information providers, including search engines like Google and even medical professionals. This trend highlights a significant technological shift, as individuals turn to AI for diagnosis, treatment suggestions, and general medical inquiries. For investors, this represents a double-edged sword: while it signals potential disruption and innovation within the healthcare information technology sector, it also introduces considerable risks related to liability, data privacy, and the critical need for verifiable accuracy. The implications for public health are substantial, as misinformation from AI could lead to inappropriate self-treatment or delayed professional care. Companies developing these AI models, or those integrating them into healthcare platforms, face heightened scrutiny regarding the ethical deployment and rigorous validation of their outputs. Existing healthcare providers and pharmaceutical companies must consider how to adapt to this new paradigm, potentially by integrating AI tools responsibly or by emphasizing human-led medical consultation. Looking ahead, the market will closely watch how regulatory bodies, such as the FDA in the U.S. and similar agencies globally, will address the oversight and certification of AI-driven medical advice. The development of industry standards for AI accuracy and the implementation of robust disclaimers and human-in-the-loop validation processes will be crucial metrics for investors assessing the long-term viability and ethical standing of companies operating in this nascent, but rapidly expanding, sector.